E

ErVimmune

Latest funding round: 19 M$

E

• City : Lyon
• Round : Série A
• Sector : Health
• Sector : AI

ErVimmune develops cancer vaccines and T-cell therapies. Its immunotherapies target so-called cold tumours that respond poorly to current treatments.